Mostrar el registro sencillo del ítem

Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal

dc.rights.licenseopenen_US
dc.contributor.authorROLLOT, Fabien
dc.contributor.authorCOUTURIER, Justine
dc.contributor.authorCASEY, Romain
dc.contributor.authorWIERTLEWSKI, Sandrine
dc.contributor.authorDEBOUVERIE, Marc
dc.contributor.authorPELLETIER, Jean
dc.contributor.authorDE SEZE, Jerome
dc.contributor.authorLABAUGE, Pierre
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorRUET, Aurelie
dc.contributor.authorTHOUVENOT, Eric
dc.contributor.authorCIRON, Jonathan
dc.contributor.authorBERGER, Eric
dc.contributor.authorGOUT, Olivier
dc.contributor.authorCLAVELOU, Pierre
dc.contributor.authorSTANKOFF, Bruno
dc.contributor.authorCASEZ, Olivier
dc.contributor.authorBOURRE, Bertrand
dc.contributor.authorZEPHIR, Helene
dc.contributor.authorMOREAU, Thibault
dc.contributor.authorLEBRUN-FRENAY, Christine
dc.contributor.authorMAILLART, Elisabeth
dc.contributor.authorEDAN, Gilles
dc.contributor.authorNEAU, Jean-Philippe
dc.contributor.authorMONTCUQUET, Alexis
dc.contributor.authorCABRE, Philippe
dc.contributor.authorCAMDESSANCHE, Jean-Philippe
dc.contributor.authorDEFER, Gilles
dc.contributor.authorNASR, Halfa Ben
dc.contributor.authorMAUROUSSET, Aude
dc.contributor.authorHANKIEWICZ, Karolina
dc.contributor.authorPOTTIER, Corinne
dc.contributor.authorLERAY, Emmanuelle
dc.contributor.authorVUKUSIC, Sandra
dc.contributor.authorLAPLAUD, David-Axel
dc.date.accessioned2023-03-24T13:35:50Z
dc.date.available2023-03-24T13:35:50Z
dc.date.issued2022-03
dc.identifier.issn1933-7213en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/172415
dc.description.abstractEnIn France, two therapeutic strategies can be offered after fingolimod (FNG) withdrawal to highly active relapsing–remitting multiple sclerosis (RRMS) patients: natalizumab (NTZ) or anti-CD20. We compared the effectiveness of these two strategies as a switch for FNG within the OFSEP database. The primary endpoint was the time to first relapse. Other outcomes were the relapse rates over 3-month periods, time to worsening the EDSS score, proportion of patients with worsened 24-month MRI, time to treatment discontinuation, and incidence rates of serious adverse events. The dynamics of event rates over time were modeled using multidimensional penalized splines, allowing the possibility to model the effects of covariates in a flexible way, considering non-linearity and interactions. A total of 740 patients were included (337 under anti-CD20 and 403 under NTZ). There was no difference between the two treatments regarding the dynamic of the first occurrence of relapse, with a monthly probability of 5.0% at initiation and 1.0% after 6 months. The rate of EDSS worsening increased in both groups until 6 months and then decreased. No difference in the proportion of patients with new T2 lesions at 24 months was observed. After 18 months of follow-up, a greater risk of NTZ discontinuation was found compared to anti-CD20. This study showed no difference between NTZ and anti-CD20 after the FNG switch regarding the clinical and radiological activity. The effect of these treatments was optimal after 6 months and there was more frequent discontinuation of NTZ after 18 months, probably mainly related to JC virus seroconversions. © 2022, The American Society for Experimental NeuroTherapeutics, Inc.
dc.description.sponsorshipObservatoire Français de la Sclérose en Plaques - ANR-10-COHO-0002en_US
dc.language.isoENen_US
dc.subject.enAnti-CD20
dc.subject.enEffectiveness
dc.subject.enFingolimod
dc.subject.enFlexible model
dc.subject.enMultiple sclerosis
dc.subject.enNatalizumab
dc.subject.enTherapeutics
dc.title.enComparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal
dc.title.alternativeNeurotherapeuticsen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s13311-022-01202-1en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed35217934en_US
bordeaux.journalNeurotherapeuticsen_US
bordeaux.page476-490en_US
bordeaux.volume19en_US
bordeaux.hal.laboratoriesNeurocentre Magendie - U1215en_US
bordeaux.issue2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionCHU de Bordeauxen_US
bordeaux.teamRelations glie-neuroneen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Neurotherapeutics&rft.date=2022-03&rft.volume=19&rft.issue=2&rft.spage=476-490&rft.epage=476-490&rft.eissn=1933-7213&rft.issn=1933-7213&rft.au=ROLLOT,%20Fabien&COUTURIER,%20Justine&CASEY,%20Romain&WIERTLEWSKI,%20Sandrine&DEBOUVERIE,%20Marc&rft.genre=article


Archivos en el ítem

Thumbnail
Nombre:
MAGENDIE_Neurotherapeutics_202 ...
Tamaño:
2.187Mb
Formato:
PDF
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem